West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...
Discover why GLAD's premium to NAV is unjustified. Weak earnings, poor dividend coverage, and portfolio risks suggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback